The Medical Research Council Myeloma IX trial: the impact on treatment paradigms*

Osteolytic bone disease is a hallmark of symptomatic multiple myeloma. Bisphosphonates have been the mainstay of treatment to preserve skeletal integrity and prevent skeletal-related events in patients with myeloma-related bone disease. Recently, the MRC Myeloma IX trial demonstrated for the first time improved survival and delayed disease progression with the use of an intravenous amino-bisphosphonate, zoledronic acid, vs. an oral agent, clodronate, with intensive and non-intensive anti-myeloma treatment regimens in patients with newly diagnosed multiple myeloma. These results validate a large body of preclinical, translational and other clinical data suggesting anti-myeloma effects of amino-bisphosphonates. In addition, this trial also provided the first head-to-head evidence for superiority of one bisphosphonate over another (zoledronic acid vs. clodronate) for reducing skeletal morbidity in patients with multiple myeloma, as well as a prospective comparison of toxicities. Despite the use of non-bortezomib containing anti-myeloma treatment regimens in the MRC Myeloma IX trial, these results are encouraging and provide an impetus to continue to evaluate current treatment guidelines for myeloma-associated bone disease

Fabrication And Testing Of Hybrid Fiber Compositematerial

The use of hybrid composite material hasincreasing inourday to day life. The hybrid composite are the materialsprepared by mixing twoor morematerials of different forms having higher strength and resistant to weight. Here in this paper we havetaken natural fibers like wood powder, corn husk and paddy husk.These are been fabricated with epoxy resinLY556 and catalyst HY 951.The properties of hybrid composite are compared against the tensile and compression strength. Out of which the one that is fabricated with 50% wood power and 50% corn huskcomposite materialshowed equally good results when compared with that of wood powder composite

Comparative Analysis of Functional Outcome in Patients Who Undergo Total Knee Arthroplasty with or Without Patellar Resurfacing

TKA is one option to relieve pain and to restore function to an arthritic knee. The decision to resurface the patella during TKA remains controversial. We have performed this clinical trial study to examine the efficacy and short term outcomes of TKA with and without patellar resurfacing. To compare -the functional outcome in patients who underwent TKR with patellar resurfacing or without patellar resurfacing. To compare frequency and severity of anterior knee pain and other complications in both groups (TKA with or without PR). The study was conducted on 68 patients in department of orthopedics at DMC Ludhiana. The study was divided into two groups. Patients who underwent resurfacing(n=14) and who did not undergo resurfacing of patella(n=54) Pre-op and Post-op pro forma (at minimum six months of follow up), and WOMAC score was recorded to assess various factors which affect patient satisfaction. Significant difference was observed on comparing the WOMAC score preoperative and 4 weeks after surgery with WOMAC score after 4 weeks being significantly less then preoperative WOMAC score. At 24 weeks follow up the WOMAC score in patients with patellar resurfacing was significantly less (1.29±2.16) than the other group (3.35±3.19)